Raymond Fucini

A passionate scientist with 25+ years of experience architecting and implementing cutting-edge drug discovery platforms. My pioneering work includes the development and application of direct-to-biology approaches (D2B), high-throughput synthesis and screening, and fragment-based tethering technologies. My contributions have been pivotal in advancing novel therapeutics, including the application of Chemotype Evolution for the discovery of multiple classes of clinical-stage GLP-1R agonists and a groundbreaking covalent KRAS-targeting drug. As Co-founder of Kimia Therapeutics, I currently lead a dynamic team focused on the design and application of advanced high-throughput chemical synthesis and screening technologies for Kimia's AI/ML enabled ATLAS platform. Open to discussing advancements in high throughput drug discovery workflows and potential collaborations